Nov Inc (NOV) Stock Price, Quote & News

Company Profile

NOV Inc. designs, constructs, manufactures, and sells systems, components, and products for oil and gas drilling and production, and industrial and renewable energy sectors in the United States and internationally. It operates through two segments, Energy Equipment, and Energy Products and Services. The Energy Equipment segment offers equipment and systems, spare parts, repair, and rentals; hydration units, chemical additive systems, blenders, and control systems, as well as centrifugal pumps, v...

Industry: Oil & Gas Equipment & Services

Sector: Energy

Phone: 346 223 3000

Website: www.nov.com

Address:

10353 Richmond Avenue, Houston, United States

highnihilism Oct. 3 at 7:32 PM

0 · Reply

clan Sep. 30 at 6:46 PM

$MNKD $GSK $NOV $TAK $MRK This re-manufactured Clofazimine in inhalation form(s) is going to be HUGE for MannKind! Oct. 2025 publication in the Journal Of Pharmaceutical Sciences -- link --> Pulmonary drug delivery of clofazimine: A route of administration and pharmacokinetics guided repositioning strategy against drug resistant tuberculosis informed by use for other disease indications - ScienceDirect https://share.google/PQ72yMfXnstl0IBax

0 · Reply

Token859 Sep. 30 at 5:36 PM

$NOV NVO-If this hold, may be last chance to be greedy Minor dip to monthly SMA 100 for the second time recently. If support holds again, expect a strong upward move.

0 · Reply

highnihilism Sep. 30 at 10:38 AM

$FLD Fold Holdings: 141 trades, $43K vs $16K avg (2.70x). $27K calls / $16K puts. $NOV Nov: 101 trades, $34K vs $86K avg (0.39x !). $27K calls / $7K puts. $GSHD Goosehead Insurance: 16 trades, $27K vs $68K avg (0.40x !). $26K calls / $1K puts. $TIGO Millicom Intl Cellular: 26 trades, $26K vs $168K avg (0.16x !!). $26K calls / $0.08K puts.

0 · Reply

clan Sep. 29 at 5:36 PM

$MNKD CLOFAZIMINE (CIS) by Mannkind --------------------------------------------------- Designations: - Phase 3 ICoN-1 international trials • U.S.A. & Japan & Australia & Korea - Fast Tracked by FDA - Orpan Drug - Qualified Infectious Disease Product - Well tolerated - No significant Adverse Events - Localized treatment (lungs) - Improved patient adherence - Indications for arthritis & CANCERs - Current global mkt $2.3B [2023] {even with the adverse events (AEs) caused by other pharmas' current formulations} ...and coming soon..... - - - Clofazimine DPI Partner with $GSK ? $NOV ? $TAK ? Maybe $MRK ?

0 · Reply

im_ichiban Sep. 28 at 8:25 PM

$DEO Warren Buffet $BRK.A disclosed 10% stake like $UNH? Mr Buffet like dividend king $NOV

1 · Reply

HANR Sep. 26 at 7:11 PM

$IXHL $RMD $NOV $JAZZ I swear I have never seen a shorter as stupid as you You think a stock drop equals a failed drug That is pure ignorance The market is manipulated by whales while the only truth is written in the clinical data The drug showed 83% efficacy numbers you or a hundred like you cannot argue with If your shallow brain believes share price down equals drug does not work then you do not belong here you belong reading fairy tales Get ready to witness the biggest slap in your life when the FDA and a big acquirer prove you are nothing but a dumb crushed short with zero value

1 · Reply

va4f6 Sep. 26 at 6:25 PM

$IXHL $RMD $NOV $JAZZ

0 · Reply

va4f6 Sep. 26 at 5:43 PM

$IXHL So $IXHL REPOSA Advisory Board has THREE Big Pharma doctors from $RMD $NOV $JAZZ each have their TOP (OSA) Sleep Apnea doctors on the $IXHL REPOSA Advisory Board for a massive reason! REPOSA Phase 2 results were outstanding with NO SIDE EFFECTS!! Doctor Williams from $NOV has a incentive package if REPOSA (pill form therapy) is bought out for $5 Billion Dollars and an even larger incentive package if REPOSA is bought out for $10 Billion Dollars!!! NOW lets discuss the $IXHL BOD's cancelling 347M Class A Warrants AND right after initiating a 20M share buyback SPELLS BIG PHARMA PARTNERSHIP/BUYOUT COMING!! No way BOD's cancelled and paid off all future debt & dilution and initiate a buyback without a Big Pharma DEAL FINALIZED!! Writings on the wall!!

0 · Reply

ZacksResearch Sep. 24 at 6:28 PM

Time to dump $NOV? 🚨 Profit slump, shrinking margins, and weak orders all point to mounting risks with limited upside. See the full sell case here 👉 https://www.zacks.com/stock/news/2756600/heres-why-investors-should-consider-selling-nov-stock-now?cid=sm-stocktwits-2-2756600-teaser-14014&ADID=SYND_STOCKTWITS_TWEET_2_2756600_TEASER_14014

0 · Reply

NOV Announces Third Quarter 2025 Earnings Conference Call

Aug 14, 2025, 6:30 AM EDT - 7 weeks ago

NOV Declares Regular Quarterly Dividend

Jul 29, 2025, 5:08 PM EDT - 2 months ago

NOV Inc. (NOV) Q2 2025 Earnings Conference Call Transcript

Jul 28, 2025, 5:45 PM EDT - 2 months ago

NOV Reports Second Quarter 2025 Results

Jul 9, 2025, 12:47 AM EDT - 3 months ago

NOV: Growth Proposition Intact Despite Near-Term Headwind

Jun 27, 2025, 6:30 AM EDT - 3 months ago

NOV Announces Second Quarter 2025 Earnings Conference Call

May 21, 2025, 6:30 AM EDT - 4 months ago

NOV Declares Regular Quarterly Dividend and Supplemental Dividend

Apr 29, 2025, 12:44 PM EDT - 5 months ago

NOV Inc. (NOV) Q1 2025 Earnings Call Transcript

Apr 28, 2025, 5:45 PM EDT - 5 months ago

NOV Reports First Quarter 2025 Results

Mar 19, 2025, 5:00 PM EDT - 7 months ago

NOV Announces Key Leadership Changes

Feb 7, 2025, 3:21 PM EST - 8 months ago

NOV: Shareholder Returns Have Likely Peaked For Now

Feb 5, 2025, 3:12 PM EST - 8 months ago

NOV Inc. (NOV) Q4 2024 Earnings Call Transcript

Feb 4, 2025, 5:45 PM EST - 8 months ago

NOV Reports Fourth Quarter and Full-Year 2024 Earnings

Dec 23, 2024, 6:30 AM EST - 10 months ago

NOV Announces Fourth Quarter and Full Year 2024 Earnings Conference Call

Dec 16, 2024, 6:30 AM EST - 10 months ago

NOV Appoints Chris Kendall to the Board of Directors

Dec 5, 2024, 12:27 PM EST - 10 months ago

The Big 3: DJT, JD, NOV

DJT JD

Nov 12, 2024, 2:11 PM EST - 11 months ago

Venture Builder VC Launches NOV Supernova Accelerator to Drive Digital Transformation in Upstream Oil & Gas with Disruptive Startups

Oct 28, 2024, 11:06 AM EDT - 1 year ago

These Analysts Lower Their Forecasts On NOV Following Q3 Results

Oct 25, 2024, 2:55 PM EDT - 1 year ago

NOV Inc. (NOV) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 5:45 PM EDT - 1 year ago

NOV Reports Third Quarter 2024 Results

Sep 30, 2024, 11:11 AM EDT - 1 year ago

14 energy stocks whose ample cash flow might benefit shareholders

BTU CHRD COP DVN FANG HAL LBRT

Sep 23, 2024, 6:30 AM EDT - 1 year ago

NOV Announces Third Quarter 2024 Earnings Conference Call

Jul 26, 2024, 3:27 PM EDT - 1 year ago

NOV Inc. (NOV) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 6:00 PM EDT - 1 year ago

NOV Reports Second Quarter 2024 Results

Jul 22, 2024, 11:23 AM EDT - 1 year ago

6 Stocks That Have Come Too Far, Too Fast

BJRI COOP CUBI MXL SAH

Jul 9, 2024, 5:28 PM EDT - 1 year ago

NOV: A Top Oil And Gas Services Pick Under Quiet Accumulation

Jun 21, 2024, 6:30 AM EDT - 1 year ago

NOV Announces Second Quarter 2024 Earnings Conference Call

May 16, 2024, 6:30 AM EDT - 1 year ago

NOV Announces 50 Percent Increase in Regular Quarterly Dividend

Apr 26, 2024, 3:50 PM EDT - 1 year ago

NOV Inc. (NOV) Q1 2024 Earnings Call Transcript

Apr 25, 2024, 6:09 PM EDT - 1 year ago

NOV Reports First Quarter 2024 Results, Return of Capital Framework, $1 Billion Share Repurchase Authorization, and Plan to Increase Dividend 50%

Apr 15, 2024, 1:14 PM EDT - 1 year ago

Bullish on NOV

Apr 9, 2024, 4:15 PM EDT - 1 year ago

Arcosa, Inc. Announces Completion of Ameron Acquisition

ACA

Mar 26, 2024, 6:30 AM EDT - 1 year ago

NOV Announces First Quarter 2024 Earnings Conference Call

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Arcosa Announces Agreement to Acquire Ameron Pole Products from NOV Inc.

ACA

Feb 22, 2024, 4:34 PM EST - 1 year ago

NOV Announces Opening of Regional Headquarters in Dammam, Saudi Arabia

Feb 2, 2024, 1:58 PM EST - 1 year ago

NOV Inc. (NOV) Q4 2023 Earnings Call Transcript

Feb 1, 2024, 5:30 PM EST - 1 year ago

NOV Reports Fourth Quarter and Full Year 2023 Earnings

Oct 27, 2023, 12:37 PM EDT - 2 years ago

NOV Inc. (NOV) Q3 2023 Earnings Call Transcript

Oct 26, 2023, 5:00 PM EDT - 2 years ago

NOV Reports Third Quarter 2023 Earnings

Sep 12, 2023, 11:48 AM EDT - 2 years ago

NOV Announces Third Quarter 2023 Earnings Conference Call

Aug 15, 2023, 11:00 AM EDT - 2 years ago

Selling Time? Oil, Inflation, Debt Concerns And A T-Bill Portfolio

BBSA BIL BILS DIA EDV EGF EWJ

Jul 27, 2023, 3:44 PM EDT - 2 years ago

NOV Inc. (NOV) Q2 2023 Earnings Call Transcript

Jul 26, 2023, 5:00 PM EDT - 2 years ago

NOV Reports Second Quarter 2023 Earnings

Jun 13, 2023, 6:00 PM EDT - 2 years ago

NOV Announces Second Quarter 2023 Earnings Conference Call

May 3, 2023, 9:30 AM EDT - 2 years ago

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NOV Inc. and Encourages Investors with Losses to Contact the Firm

Apr 27, 2023, 4:20 PM EDT - 2 years ago

NOV Inc. (NOV) Q1 2023 Earnings Call Transcript

Apr 26, 2023, 5:00 PM EDT - 2 years ago

NOV Reports First Quarter 2023 Earnings

Mar 27, 2023, 5:43 PM EDT - 2 years ago

NOV: 2023 Off To A Bad Start

Mar 27, 2023, 11:36 AM EDT - 2 years ago

NOV: Shares Still A Value Ahead Of Earnings, At A Key Spot Technically

highnihilism Oct. 3 at 7:32 PM

0 · Reply

clan Sep. 30 at 6:46 PM

0 · Reply

Token859 Sep. 30 at 5:36 PM

$NOV NVO-If this hold, may be last chance to be greedy Minor dip to monthly SMA 100 for the second time recently. If support holds again, expect a strong upward move.

0 · Reply

highnihilism Sep. 30 at 10:38 AM

0 · Reply

clan Sep. 29 at 5:36 PM

0 · Reply

im_ichiban Sep. 28 at 8:25 PM

$DEO Warren Buffet $BRK.A disclosed 10% stake like $UNH? Mr Buffet like dividend king $NOV

1 · Reply

HANR Sep. 26 at 7:11 PM

1 · Reply

va4f6 Sep. 26 at 6:25 PM

$IXHL $RMD $NOV $JAZZ

0 · Reply

va4f6 Sep. 26 at 5:43 PM

0 · Reply

ZacksResearch Sep. 24 at 6:28 PM

0 · Reply

ZacksResearch Sep. 24 at 5:28 PM

$NOV struggles continue — why this might be a sell-off signal 📉 NOV's shares have fallen 22% over the past year, with the Zacks Consensus Estimate for 2025 earnings revised down by 9.1% from $1.10 to $1, indicating a challenging outlook compared to peers like USA Compression and Oil States. The ongoing decline in profitability and margins, coupled with a weak order book, highlight significant risks. Understand the risks before investing in NOV 👉 https://www.zacks.com/stock/news/2756600/heres-why-investors-should-consider-selling-nov-stock-now?cid=sm-stocktwits-2-2756600-body-14006&ADID=SYND_STOCKTWITS_TWEET_2_2756600_BODY_14006

0 · Reply

fibonacci6180 Sep. 24 at 2:49 AM

$NOV Trading idea - Entry point > 12.7/61.80% https://fibonacci6180.com/2025/09/23/nov-chart-fibonacci-analysis-092325/

0 · Reply

JP73 Sep. 23 at 9:29 PM

$CRK $NOV ... Market was down , energy was up and these 2 significantly over performed the market and sector.

1 · Reply

ZacksResearch Sep. 23 at 4:18 PM

$NOV just landed a game-changing contract 🌎⚡ They’ll supply their SSY system for Argentina’s first-ever offshore FLNG project in the Gulf of San Matias — a massive milestone. See why this deal could be a long-term catalyst 👉 https://www.zacks.com/stock/news/2755569/nov-secures-key-contract-for-argentinas-first-flng-project?cid=sm-stocktwits-2-2755569-teaser-13717&ADID=SYND_STOCKTWITS_TWEET_2_2755569_TEASER_13717

0 · Reply

ZacksResearch Sep. 23 at 3:18 PM

$NOV secures a significant contract for Argentina's first offshore FLNG project! 🌊 🏗️ The APL SSY system is set to enhance efficiency with a jetty-free design, reducing costs and streamlining logistics. 🇦🇷 This marks NOV's strategic entry into Argentina's energy sector, reinforcing its global offshore LNG footprint. Explore how NOV's technology supports energy initiatives 👉 https://www.zacks.com/stock/news/2755569/nov-secures-key-contract-for-argentinas-first-flng-project?cid=sm-stocktwits-2-2755569-body-13715&ADID=SYND_STOCKTWITS_TWEET_2_2755569_BODY_13715

0 · Reply

TheLongVol Sep. 23 at 2:37 PM

$VLO $NOV $XOM all going to outperform back end of this year...

0 · Reply

clan Sep. 23 at 1:16 AM

$MNKD An update on the Clofazimine trial being fully-enrolled s/b heard any day now. Coming to market in 2026. CLOFAZIMINE (CIS) by Mannkind ---------------------------------------------- Designations: - Phase 3 ICoN-1 international trials • U.S.A. & Japan & Australia & Korea - Fast Tracked by FDA - Orpan Drug - Qualified Infectious Disease Product - Well tolerated - No significant Adverse Events - Localized treatment (lungs) - Improved patient adherence - Indications for arthritis & CANCERs - Current global mkt $2.3B [2023] {even with the adverse events (AEs) caused by other pharmas' current formulations} ...and coming not long after..... - - - Clofazimine DPI Partner with $GSK ? $NOV ? ROCHE ? Maybe $MRK ?

1 · Reply

APMMDT Sep. 22 at 3:16 AM

$IXHL Agreed. Lookin at $NOV history, the last company they acquired was in 2024. Also most of the companies they acquired were in p2 at the time of acquisition. With ~20B in cash I believe chances of $NOV aquaring us is more than $RMD.

2 · Reply

JP73 Sep. 20 at 2:51 PM

$NOV Thomas Hayes , Hedge Fund Tips on NOV. Impressive presentation. NOV section starts at 1:11:17 and his energy comments at apprx 1:02. Energy as a % of the S&P 500 is less than 3%, an all time low. https://youtu.be/ZeAAMeS3DvM?si=Oo_vrLiBK7t0SSyd

0 · Reply

TalkMarkets Sep. 19 at 12:07 AM

“The Fuel Behind The Future” Stock Market (And Sentiment Results) $CRK $NOV https://talkmarkets.com/content/stocks--equities/the-fuel-behind-the-future-stock-market-and-sentiment-results?post=523473

0 · Reply

highnihilism Sep. 16 at 3:17 PM

Oil → $FTI Technipfmc $PTEN Patterson-Uti Energy $TS Tenaris $LBRT Liberty Energy $NOV Nov

0 · Reply

VectorVictor Sep. 16 at 12:34 AM

$ACN Accenture by another name - $NOV - I’m long and fucked!

0 · Reply

Market Cap	5.09B
Revenue (ttm)	8.87B
Net Income (ttm)	635.00M
EPS (ttm)	N/A
PE Ratio	10.84
Forward PE	13.22
Profit Margin	7.16%
Debt to Equity Ratio	0.26

Volume	3,904,800
Avg Vol	3,773,462
Day's Range	N/A - N/A
Shares Out	371.37M
Stochastic %K	98%
Beta	1.26
Analysts	Sell
Price Target	$15.17